2023-07-012024-06-302024-06-30false13470737OXFORD GENELAB ACADEMY LTD2025-03-21falseiso4217:GBPxbrli:pure134707372023-07-01134707372024-06-30134707372023-07-012024-06-30134707372022-07-01134707372023-06-30134707372022-07-012023-06-3013470737bus:SmallEntities2023-07-012024-06-3013470737bus:AuditExempt-NoAccountantsReport2023-07-012024-06-3013470737bus:AbridgedAccounts2023-07-012024-06-3013470737bus:PrivateLimitedCompanyLtd2023-07-012024-06-3013470737core:WithinOneYear2024-06-3013470737core:AfterOneYear2024-06-3013470737core:WithinOneYear2023-06-3013470737core:AfterOneYear2023-06-3013470737core:ShareCapital2024-06-3013470737core:SharePremium2024-06-3013470737core:RevaluationReserve2024-06-3013470737core:OtherReservesSubtotal2024-06-3013470737core:RetainedEarningsAccumulatedLosses2024-06-3013470737core:ShareCapital2023-06-3013470737core:SharePremium2023-06-3013470737core:RevaluationReserve2023-06-3013470737core:OtherReservesSubtotal2023-06-3013470737core:RetainedEarningsAccumulatedLosses2023-06-3013470737core:LandBuildings2024-06-3013470737core:PlantMachinery2024-06-3013470737core:Vehicles2024-06-3013470737core:FurnitureFittings2024-06-3013470737core:OfficeEquipment2024-06-3013470737core:NetGoodwill2024-06-3013470737core:IntangibleAssetsOtherThanGoodwill2024-06-3013470737core:ListedExchangeTraded2024-06-3013470737core:UnlistedNon-exchangeTraded2024-06-3013470737core:LandBuildings2023-06-3013470737core:PlantMachinery2023-06-3013470737core:Vehicles2023-06-3013470737core:FurnitureFittings2023-06-3013470737core:OfficeEquipment2023-06-3013470737core:NetGoodwill2023-06-3013470737core:IntangibleAssetsOtherThanGoodwill2023-06-3013470737core:ListedExchangeTraded2023-06-3013470737core:UnlistedNon-exchangeTraded2023-06-3013470737core:LandBuildings2023-07-012024-06-3013470737core:PlantMachinery2023-07-012024-06-3013470737core:Vehicles2023-07-012024-06-3013470737core:FurnitureFittings2023-07-012024-06-3013470737core:OfficeEquipment2023-07-012024-06-3013470737core:NetGoodwill2023-07-012024-06-3013470737core:IntangibleAssetsOtherThanGoodwill2023-07-012024-06-3013470737core:ListedExchangeTraded2023-07-012024-06-3013470737core:UnlistedNon-exchangeTraded2023-07-012024-06-3013470737core:MoreThanFiveYears2023-07-012024-06-3013470737core:Non-currentFinancialInstruments2024-06-3013470737core:Non-currentFinancialInstruments2023-06-3013470737dpl:CostSales2023-07-012024-06-3013470737dpl:DistributionCosts2023-07-012024-06-3013470737core:LandBuildings2023-07-012024-06-3013470737core:PlantMachinery2023-07-012024-06-3013470737core:Vehicles2023-07-012024-06-3013470737core:FurnitureFittings2023-07-012024-06-3013470737core:OfficeEquipment2023-07-012024-06-3013470737dpl:AdministrativeExpenses2023-07-012024-06-3013470737core:NetGoodwill2023-07-012024-06-3013470737core:IntangibleAssetsOtherThanGoodwill2023-07-012024-06-3013470737dpl:GroupUndertakings2023-07-012024-06-3013470737dpl:ParticipatingInterests2023-07-012024-06-3013470737dpl:GroupUndertakingscore:ListedExchangeTraded2023-07-012024-06-3013470737core:ListedExchangeTraded2023-07-012024-06-3013470737dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-07-012024-06-3013470737core:UnlistedNon-exchangeTraded2023-07-012024-06-3013470737dpl:CostSales2022-07-012023-06-3013470737dpl:DistributionCosts2022-07-012023-06-3013470737core:LandBuildings2022-07-012023-06-3013470737core:PlantMachinery2022-07-012023-06-3013470737core:Vehicles2022-07-012023-06-3013470737core:FurnitureFittings2022-07-012023-06-3013470737core:OfficeEquipment2022-07-012023-06-3013470737dpl:AdministrativeExpenses2022-07-012023-06-3013470737core:NetGoodwill2022-07-012023-06-3013470737core:IntangibleAssetsOtherThanGoodwill2022-07-012023-06-3013470737dpl:GroupUndertakings2022-07-012023-06-3013470737dpl:ParticipatingInterests2022-07-012023-06-3013470737dpl:GroupUndertakingscore:ListedExchangeTraded2022-07-012023-06-3013470737core:ListedExchangeTraded2022-07-012023-06-3013470737dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-07-012023-06-3013470737core:UnlistedNon-exchangeTraded2022-07-012023-06-3013470737core:NetGoodwill2024-06-3013470737core:IntangibleAssetsOtherThanGoodwill2024-06-3013470737core:LandBuildings2024-06-3013470737core:PlantMachinery2024-06-3013470737core:Vehicles2024-06-3013470737core:FurnitureFittings2024-06-3013470737core:OfficeEquipment2024-06-3013470737core:AfterOneYear2024-06-3013470737core:WithinOneYear2024-06-3013470737core:ListedExchangeTraded2024-06-3013470737core:UnlistedNon-exchangeTraded2024-06-3013470737core:ShareCapital2024-06-3013470737core:SharePremium2024-06-3013470737core:RevaluationReserve2024-06-3013470737core:OtherReservesSubtotal2024-06-3013470737core:RetainedEarningsAccumulatedLosses2024-06-3013470737core:NetGoodwill2023-06-3013470737core:IntangibleAssetsOtherThanGoodwill2023-06-3013470737core:LandBuildings2023-06-3013470737core:PlantMachinery2023-06-3013470737core:Vehicles2023-06-3013470737core:FurnitureFittings2023-06-3013470737core:OfficeEquipment2023-06-3013470737core:AfterOneYear2023-06-3013470737core:WithinOneYear2023-06-3013470737core:ListedExchangeTraded2023-06-3013470737core:UnlistedNon-exchangeTraded2023-06-3013470737core:ShareCapital2023-06-3013470737core:SharePremium2023-06-3013470737core:RevaluationReserve2023-06-3013470737core:OtherReservesSubtotal2023-06-3013470737core:RetainedEarningsAccumulatedLosses2023-06-3013470737core:NetGoodwill2022-07-0113470737core:IntangibleAssetsOtherThanGoodwill2022-07-0113470737core:LandBuildings2022-07-0113470737core:PlantMachinery2022-07-0113470737core:Vehicles2022-07-0113470737core:FurnitureFittings2022-07-0113470737core:OfficeEquipment2022-07-0113470737core:AfterOneYear2022-07-0113470737core:WithinOneYear2022-07-0113470737core:ListedExchangeTraded2022-07-0113470737core:UnlistedNon-exchangeTraded2022-07-0113470737core:ShareCapital2022-07-0113470737core:SharePremium2022-07-0113470737core:RevaluationReserve2022-07-0113470737core:OtherReservesSubtotal2022-07-0113470737core:RetainedEarningsAccumulatedLosses2022-07-0113470737core:AfterOneYear2023-07-012024-06-3013470737core:WithinOneYear2023-07-012024-06-3013470737core:Non-currentFinancialInstrumentscore:CostValuation2023-07-012024-06-3013470737core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-07-012024-06-3013470737core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-07-012024-06-3013470737core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-07-012024-06-3013470737core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-07-012024-06-3013470737core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-07-012024-06-3013470737core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-07-012024-06-3013470737core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-07-012024-06-3013470737core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-07-012024-06-3013470737core:Non-currentFinancialInstrumentscore:CostValuation2024-06-3013470737core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-06-3013470737core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-06-3013470737core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-06-3013470737core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-06-3013470737core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-06-3013470737core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-06-3013470737core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-06-3013470737core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-06-3013470737core:Non-currentFinancialInstrumentscore:CostValuation2023-06-3013470737core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-06-3013470737core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-06-3013470737core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-06-3013470737core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-06-3013470737core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-06-3013470737core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-06-3013470737core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-06-3013470737core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-06-3013470737bus:Director12023-07-012024-06-30

OXFORD GENELAB ACADEMY LTD

Registered Number
13470737
(England and Wales)

Unaudited Financial Statements for the Year ended
30 June 2024

OXFORD GENELAB ACADEMY LTD
Company Information
for the year from 1 July 2023 to 30 June 2024

Director

ZHOU, Lu, Dr

Registered Address

John Eccles House
Robert Robinson Avenue
Oxford
OX4 4GP

Registered Number

13470737 (England and Wales)
OXFORD GENELAB ACADEMY LTD
Balance Sheet as at
30 June 2024

Notes

2024

2023

£

£

£

£

Current assets
Debtors1,600-
Cash at bank and on hand50,7591,478
52,3591,478
Creditors amounts falling due within one year(99,465)(11,269)
Net current assets (liabilities)(47,106)(9,791)
Total assets less current liabilities(47,106)(9,791)
Net assets(47,106)(9,791)
Capital and reserves
Called up share capital11
Profit and loss account(47,107)(9,792)
Shareholders' funds(47,106)(9,791)
The financial statements were approved and authorised for issue by the Director on 21 March 2025, and are signed on its behalf by:
ZHOU, Lu, Dr
Director
Registered Company No. 13470737
OXFORD GENELAB ACADEMY LTD
Notes to the Financial Statements
for the year ended 30 June 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Going concern
After reviewing the company's forecasts and projections, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The company therefore continues to adopt the going concern basis of accounting in preparing its financial statements.
Revenue from sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
2.Average number of employees

20242023
Average number of employees during the year10
3.Related party transactions
Transactions with director mainly arose business expenses paid on behalf of the company. Dr. Zhou is the managing director who transferred his majority shares of the company to Santo Therapeutics Co. Ltd on 1 April 2024, as a result, the company is 100% owned by Santo Therapeutics Co. Ltd. No transactions with related parties were undertaken such as are required to be disclosed under FRS 102 Section 1A.